HAMI3379
Modify Date: 2024-01-08 09:50:18
HAMI3379 structure
|
Common Name | HAMI3379 | ||
|---|---|---|---|---|
| CAS Number | 1245653-57-9 | Molecular Weight | 595.733 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C34H45NO8 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of HAMI3379HAMI3379 (HAMI-3379) is a potent and selective antagonist of cysteinyl leukotriene 2 (CysLT(2)) receptor, inhibits LTD4- and LTC4-induced intracellular calcium mobilization withIC50 of 3.8 nM and 4.4 nM respectively; exhibits very low potency on a recombinant CysLT(1) receptors (IC50>10 uM), does not exhibit any agonistic activity on both CysLT receptors; concentration-dependently inhibits and reverses the LTC(4)-induced perfusion pressure increase and contractility decrease in isolated Langendorff-perfused guinea pig hearts, protects against acute brain injury after focal cerebral ischemia in rats. |
| Name | HAMI3379 |
|---|
| Description | HAMI3379 (HAMI-3379) is a potent and selective antagonist of cysteinyl leukotriene 2 (CysLT(2)) receptor, inhibits LTD4- and LTC4-induced intracellular calcium mobilization withIC50 of 3.8 nM and 4.4 nM respectively; exhibits very low potency on a recombinant CysLT(1) receptors (IC50>10 uM), does not exhibit any agonistic activity on both CysLT receptors; concentration-dependently inhibits and reverses the LTC(4)-induced perfusion pressure increase and contractility decrease in isolated Langendorff-perfused guinea pig hearts, protects against acute brain injury after focal cerebral ischemia in rats. |
|---|---|
| References | References 1. Merten N, et al. Cell Chem Biol. 2018 Jun 21;25(6):775-786.e5. 2. Wunder F, et al. Br J Pharmacol. 2010 May;160(2):399-409. 3. Shi QJ, et al. Brain Res. 2012 Nov 12;1484:57-67. 4. Zhang XY, et al. J Pharmacol Exp Ther. 2013 Aug;346(2):328-41. View Related Products by Target Leukotriene Receptor |
| Molecular Formula | C34H45NO8 |
|---|---|
| Molecular Weight | 595.733 |